MedTrace Logo

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis

NCT06224192 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 151

Last updated 2026-03-25

No results posted yet for this study

Summary

The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneously using devices for injection.

Conditions

Interventions

COMBINATION_PRODUCT

Rocatinlimab Prefilled Syringe

Prefilled Syringe (PFS) for subcutaneous (SC) injection self-administration of rocatinlimab.

COMBINATION_PRODUCT

Rocatinlimab AI

AI for SC injection self-administration of rocatinlimab.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-02
Primary Completion
2025-04-11
Completion
2026-03-16
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Japan
  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06224192 on ClinicalTrials.gov